TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05114382

Intervention type: PROCEDURE
Group type: OTHER
Intervention: EP Procedure
Description: Intracardiac signals will be passively recorded using CathVision Cube® System in parallel with the commercial (CE marked) EP recording system during a scheduled electrophysiology procedure
Study: NCT04616911

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LIFT
Description: Ligation of the intersphincteric fistula tract
Study: NCT01403168

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OSTEOPATHY + conventional analgesic treatments
Description: 5 sessions for osteopathy are planned and will start in the 15 days following the enrollment.~The conventional analgesic treatments will be administered in the 15 days following the enrollment.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Conventional analgesic treatments
Description: These treatments will be administered in the 15 days following the enrollment. Dose and frequence will depend on patients.
Study: NCT03013504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HD201
Description: Loading dose of 8mg/kg in Cycle 1 and 6mg/kg in subsequent cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Herceptin
Description: Loading dose of 8mg/kg in Cycle 1 and 6mg/kg in subsequent cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75mg/m2 via i.v. infusion during cycles 1 to 4.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 75mg/m2 via i.v. infusion during cycles 1 to 4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: 75 mg/m2 via i.v. infusion during cycles 5-8.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: 75 mg/m2 via i.v. infusion during cycles 5-8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 500 mg/m2 via i.v. infusion during cycles 5-8.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: 500 mg/m2 via i.v. infusion during cycles 5-8.
Study: NCT00541333

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Copaxone Injection

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Copaxone Injection
Study: NCT04134078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inhaled nitric oxide
Description: Inhaled nitric oxide at 40 ppm will be administered upto 24 hours post ROSC in patient who developed in hospital cardiac arrest
Study: NCT01275105

Intervention type: DRUG
Group type: OTHER
Intervention: Vehicle
Description: one drop in each eye at designated visits

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brimonidine Tartrate 0.01%
Description: one drop in each eye at designated visits

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brimonidine Tartrate 0.025%
Description: one drop in each eye at designated visits

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxymetazoline HCl 0.025%
Description: one drop in each eye at designated visits
Study: NCT00878215

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Explorer Liver Image Guided System

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Explorer Liver Image Guided System

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Explorer Liver Passive Tracking

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Explorer Liver Passive Tracking

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Explorer Liver Passive Tracking

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Explorer Liver Passive Tracking

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver surgery
Description: -Standard of care

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver surgery
Description: -Standard of care

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver surgery
Description: -Standard of care

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver abalation
Description: -Standard of care

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver abalation
Description: -Standard of care
Study: NCT02163993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galcanezumab
Description: Administered SQ

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galcanezumab
Description: Administered SQ

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galcanezumab
Description: Administered SQ

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galcanezumab
Description: Administered SQ

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SQ
Study: NCT02472691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide (investigational drug) will be added to standard of care (Aza and DLI) starting from day 1 for 21 days every 28 days for a maximum of 8 cycles. Starting dose of Lenalidomide 2.5 mg per day for the first 10 patients. If no dose limiting toxicity is identified in a first interim analysis, the next 10 patients will be treated with 5 mg per day. In case of no DLT after a second interim analysis, the remaining 30 patients are envisaged to be treated with 5 mg per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Starting on day 1 all patients will receive Azacitidine (standard of care) 75 mg/m2/d for 7 days every 28 days for up to 8 cycles.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Donor Lymphocyte Infusions
Description: DLIs will be given after cycle 4, 6 and 8 at a dose of 0.5-1x10\^6 CD3/kg (1st DLI), 1-5x10\^6 CD3/kg (2nd DLI) and 5-15x10\^6 CD3/kg (3rd DLI).
Study: NCT02822534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP2086
Description: the study has 3 doses groups and the 24 subjects were administrated SP2086 50mg,100mg,200mg respectively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP2086
Description: the study has 3 doses groups and the 24 subjects were administrated SP2086 50mg,100mg,200mg respectively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP2086
Description: the study has 3 doses groups and the 24 subjects were administrated SP2086 50mg,100mg,200mg respectively.
Study: NCT00992784

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK investigational vaccine 2186877A
Description: Single dose, intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FluarixTM
Description: Single dose, intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FluarixTM
Description: Single dose, intramuscular injection
Study: NCT00432094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Days -6, -5, -4: 500mg/m2\^/day intravenously (IV) over 60 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: 600mg/m\^2/day intravenously (IV) over 60 minutes on Days -6 through -3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Description: 2500 mg/m\^2/day continuous infusion intravenously on Days -6, -5 and -4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: 225 mg/m\^2 intravenous over 3 hours on Day -7.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thiotepa
Description: 150mg/m\^2/day intravenously IV over 30 minutes; Days -6, -5 and -4
Study: NCT02868268

Intervention type: OTHER
Intervention: Gene panel sequencing of tumor specimens
Description: Archival or biopsied tumor specimens will undergo gene panel sequencing to identify subgroups with targetable genetic (ALK, MAPK pathway, Metabolic-related genes) and/or immunologic (tumor associated macrophage infiltration, PD-L1 expression) biomarkers in neuroblastoma. A clinical report will be provided to subjects/subject physician detailing observed mutations and identified NBL subgroups and information on clinical trials that best match them. Subjects will be followed and data collected on treatments administered for one year after receipt of clinical report.
Study: NCT06677177

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nano-water, Tamsulosin Dutasteride
Description: Nano-water, given in a dose of 20 ml/kg daily for a period of 3 months Tamsulosin capsule in a dose of 0.4mg daily for a period of 3 months Dutasteride tablet in a dose of 0.5mg daily for a period of 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regular water, tamsulosin, Dutasteride
Description: Regular water, given in a dose of 20 ml/kg daily for a period of 3 months Tamsulosin capsule in a dose of 0.4mg daily for a period of 3 months Dutasteride tablet in a dose of 0.5mg daily for a period of 3 months
Study: NCT04053816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Potassium
Description: The trial treatment will start when patients are admitted to the intensive care unit after their surgery. The patient will undergo regular blood investigations, as per current practice. The frequency of K+ monitoring while on ICU will be according to clinician / nursing staff preference.~Potassium supplementation will be according to local hospital protocols. This can be either via an intravenous infusion or as a tablet. Patients will otherwise be treated as per current hospital protocol.
Study: NCT01014624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel
Description: Prasugrel 10mg tablet administered once daily for 7 days.~After a 1-day to 14-day screening period, participants will receive active treatment with either prasugrel or clopidogrel for 7 days. If a participant has not missed more than 1 dose of study medication and is unable to attend Visit 3 (Washout Day 1) the day after the 7th day of study medication, the participant may take up to an additional 3 days of study medication and proceed to Visit 3 the day after the last dose. Active treatment will be followed by a 1-day to 12-day Washout Period depending on the time to reach both of the exit criteria.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel 75 mg tablet administered once daily for 7 days.~After a 1-day to 14-day screening period, participants will receive active treatment with either prasugrel or clopidogrel for 7 days. If a participant has not missed more than 1 dose of study medication and is unable to attend Visit 3 (Washout Day 1) the day after the 7th day of study medication, the participant may take up to an additional 3 days of study medication and proceed to Visit 3 the day after the last dose. Active treatment will be followed by a 1-day to 12-day Washout Period depending on the time to reach both of the exit criteria.
Study: NCT00393120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB009471
Description: 100mg SR (sustained release) orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB009471
Description: 300mg SR (sustained release) orally once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: Orally once daily
Study: NCT00731549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole IM Depot
Description: 300mg or 400mg
Study: NCT02191007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcipotriol Betamethasone ointment and Calcipotriol ointment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcipotriol Betamethasone ointment

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Calcipotriol Betamethasone ointment and Urea Cream
Study: NCT04428099

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle change promotion program
Description: The intervention consists of 8 group sessions centered on healthy physical activity, healthy diet, social life, Good Sleep Hygiene, healthy sun exposure, nature contact, how to stop ruminating, review and maintenance tips.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfullness based cognitive program
Description: The intervention consists of 8 group sessions with a mindfulness-based cognitive program

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Written Information
Description: Written information about lifestyle change suggestions

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Written Information
Description: Written information about lifestyle change suggestions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Written Information
Description: Written information about lifestyle change suggestions
Study: NCT04321798

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: Four group sessions and one individual session delivered over a period of 12 weeks in a primary care setting. Each session includes patient education and support for behaviour change as well as a supervised practical exercise component. The intervention is based upon a combination of self-determination theory and COM-B framework (capability, opportunity, motivation and behaviour) and employs motivational interviewing techniques.
Study: NCT02858648

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavior intervention with smart phone based self-monitoring
Description: Use two smartphone applications for self-monitoring of diet, physical activity, weight, and blood glucose (connected via a blue-tooth enabled glucometer), plus 11 group session and 1 individual session focused on behavioral strategies

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavior intervention with paper diary based self-monitoring
Description: Use paper diaries along with a calorie counter booklet, weight scale, food scale, and pedometer for self-monitoring of diet, physical activity, weight, and blood glucose, plus 11 group session and 1 individual session focused on behavioral strategies
Study: NCT04072549

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Free Summer Programming
Description: The summer day camps are not singularly focused, such as sport camps or academic only camps. Rather, the camps provide indoor and outdoor opportunities for children to be physically active each day, provide enrichment and academic programming, as well as provide breakfast, lunch, and snacks. To standardize programming, the schools operate their camps on the same daily schedules which are developed by the same district-level personnel, with identical programmatic content delivered across all schools. The schools also provide the same meals to all children enrolled. The meals adhere to the Summer Food Service Program nutrition guidelines and are reimbursed through existing federal food programs.
Study: NCT04467359

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ERAS
Description: Optimize physical conditions; Fasting solid diet 6h before surgery, fasting clear fluid 2 h before surgery; If there is no chief complaint of dizziness, nausea or other discomfort after the operation, warm water (no more than 100ml) can be immediately drunk. Pain management; Encourage patients to engage in early activities under the premise of effective pain control; If no dural puncture and other complications occur, the patient has no chief complaints of headache, dizziness, nausea and other discomfort, and there is no need to lie supine, the comfortable position such as semi-supine lateral supine position can be taken immediately (avoid 90-degree upright position for patients with hip joint); Prevention of thrombosis; Prevention and treatment of nausea and vomiting; Follow-up was conducted at 4 weeks, 8 weeks and 12 weeks after the operation.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Perioperative routine rehabilitation nursing
Description: Fasting and water deprivation at 12 o 'clock on the first day before surgery; Fasting water 6-8 hours after surgery; Lie flat on your pillow for 6 hours; Get out of bed activity 1 day after operation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Perioperative routine rehabilitation nursing
Description: Fasting and water deprivation at 12 o 'clock on the first day before surgery; Fasting water 6-8 hours after surgery; Lie flat on your pillow for 6 hours; Get out of bed activity 1 day after operation
Study: NCT03946020

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Guided bone regeneration with or without autologous bone
Description: Autogenous bone chips were collected. On each side a bone level implant was placed. The bone dehiscence was measured and was thereafter treated according to the GBR protocol. A resorbable native collagen was adapted to the defect.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Guided bone regeneration with or without autologous bone
Description: Autogenous bone chips were collected. On each side a bone level implant was placed. The bone dehiscence was measured and was thereafter treated according to the GBR protocol. A resorbable native collagen was adapted to the defect.
Study: NCT01606059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW-0920
Description: Dosage form: Extended release tablet Dosage: 2 tablets
Study: NCT02348190

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Lipid/heparin
Description: 32 healthy volunteers will undergo euglycemic - hyperinsulinemic clamping without radioactive isotopes and with (n=16) and without (n=16) lipid/heparin co-infusion for 8 hours.~Serial (at 0, 1, 2 and 4 h) muscle and fat biopsies and serial blood samples (q' 1 h) will be obtained. The following measurements will be obtained in muscle biopsies and T-cell extracts: PKC-βI and II and PKC-δ, IKK, IκB-α, NFκB, IRS-1 tyrosine phosphorylation, IRS-1 associated PI3- kinase, ICAM, VCAM and e-selectin mRNAs.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lipid/heparin
Description: 32 healthy volunteers will undergo euglycemic - hyperinsulinemic clamping without radioactive isotopes and with (n=16) and without (n=16) lipid/heparin co-infusion for 8 hours.~Serial (at 0, 1, 2 and 4 h) muscle and fat biopsies and serial blood samples (q' 1 h) will be obtained. The following measurements will be obtained in muscle biopsies and T-cell extracts: PKC-βI and II and PKC-δ, IKK, IκB-α, NFκB, IRS-1 tyrosine phosphorylation, IRS-1 associated PI3- kinase, ICAM, VCAM and e-selectin mRNAs.
Study: NCT01270529

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Increasing Physical activity
Description: The subjects (CKD Stages 1-4, ESRD on Hemodialysis or Peritoneal Dialysis) will continue to wear the pedometer for 12 weeks during which time he or she will be asked to gradually increase steps walked per day above baseline physical activity. The patient will be called once a week in order to monitor progress, set new weekly step goals (usually 500-1000 steps/day greater than the previous week), and also to motivate the participant.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Increasing Physical activity
Description: The subjects (CKD Stages 1-4, ESRD on Hemodialysis or Peritoneal Dialysis) will continue to wear the pedometer for 12 weeks during which time he or she will be asked to gradually increase steps walked per day above baseline physical activity. The patient will be called once a week in order to monitor progress, set new weekly step goals (usually 500-1000 steps/day greater than the previous week), and also to motivate the participant.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Increasing Physical activity
Description: The subjects (CKD Stages 1-4, ESRD on Hemodialysis or Peritoneal Dialysis) will continue to wear the pedometer for 12 weeks during which time he or she will be asked to gradually increase steps walked per day above baseline physical activity. The patient will be called once a week in order to monitor progress, set new weekly step goals (usually 500-1000 steps/day greater than the previous week), and also to motivate the participant.
Study: NCT03279107

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soluble corn fiber
Description: soluble corn fiber

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soluble corn fiber
Description: soluble corn fiber

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: maltodextrin
Description: maltodextrin

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: maltodextrin
Description: maltodextrin
Study: NCT01344343

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Accelerated surgical hip fracture repair
Description: Accelerated hip fracture surgery defined as arrival in the operation room within 6 hours of diagnosis of a hip fracture requiring surgery
Study: NCT02224170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Lidocaine 2mg Kg-1 in normal saline (total volume 25mL) was infused after tracheal intubation, and lidocaine was infused at the rate of lidocaine 2mg Kg-1 h-1 (0.2 ml Kg-1 h-1, equivalent volume as normal saline in dexamethasone group) until the end of surgery (at the time of skin closure).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone 8mg in normal saline (total volume 25mL) was infused after tracheal intubation, and normal saline was continuously infused at the rate of 0.2 ml Kg-1 h-1 until the end of surgery (at the time of skin closure).
Study: NCT03817398

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood collection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Drug Withdrawn
Description: Stop taking TKI medication

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tyrosine Kinase Inhibitor
Description: Re-start TKI medication
Study: NCT04095234

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture, a therapy of traditional Chinese medicine (TCM), involves penetrating the skin with thin, solid, metallic needles that are manipulated by hand or electrical stimulation. If the patient has an electronically charged device, they will not receive TENS stimulation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Massage
Description: Massage, which involves the manual manipulation of muscles and other soft tissue areas of the body, is one of the earliest known forms of pain relief.